APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer
/0 Comments/in Immunotherapy, Preclinical Research/by MaxA Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]
A New Genetic Engineering Tool To Revolutionize Cancer Therapies
/0 Comments/in CRISPR, Preclinical Research/by MaxKCL-HO-1i: A Novel HO-1 Inhibitor Targeting Tumor-Associated Macrophages
/0 Comments/in Preclinical Research/by MaxNew Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models
/0 Comments/in Oncolytic, Preclinical Research/by MaxPreclinical Advances in Sequencing CDK4/6 and PARP Inhibitors
/0 Comments/in Preclinical Research/by MaxUPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy
/0 Comments/in Antibody Radioconjugate, Preclinical Research/by MaxNew Combination Therapy Shows Potential for Treating MYC-Driven Cancers
/0 Comments/in Drug repurposing, Preclinical Research/by MaxLYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer
/0 Comments/in Preclinical Research, PROTACs/by MaxAI Platform Aims to Revolutionize Cancer Immunotherapy
/0 Comments/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025